---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-042057"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:39:31.003098+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics reports positive 48-week FOREST-HCM data on aficamten at ACC

## Summary
- 46 patients completed 48 weeks; 75% on 15mg or 20mg dose of aficamten.
- Mean resting LVOT-G reduced by 39.6 mmHg (p<0.0001) and Valsalva LVOT-G by 53.2 mmHg.
- 82.2% improved by ≥1 NYHA class; no worsening class observed.
- NT-proBNP decreased 63% (p<0.001); SRT-eligibility reduced 94%.
- No treatment-related SAEs; modest LVEF reduction (-5.1%) with three dose adjustments.

## SEC filing metadata
- accession: 0000950170-24-042057
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024042057/0000950170-24-042057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024042057/cytk-20240405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-042057
- JSON: https://secwatch.observer/filing/0000950170-24-042057.json
- Plain text: https://secwatch.observer/filing/0000950170-24-042057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.